Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2005
10/27/2005US20050239870 Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents
10/27/2005US20050239860 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
10/27/2005US20050239855 For therapy of cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239851 Substituted benzoxazoles as estrogenic agents
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239828 Spirocyclic amides as cannabinoid receptor modulators
10/27/2005US20050239789 2-(9-bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)-cyclobutanone; treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea
10/27/2005US20050239784 3-Phenyl analogs of toxoflavine as kinase inhibitors
10/27/2005US20050239780 Tetrahydropyran derivative
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239766 e.g. 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-{4-[N-((R)- alpha -{N-(S)-[1-(carboxy)-2-(hydroxy)ethyl]carbamoyl}benzyl)carbamoylmethoxy]phenyl}azetidin-2-one; cholesterol absorption inhibitor; hyperlipidaemia
10/27/2005US20050239741 use in the field of neuroprotection and cancer treatment (neuroblastoma tumors)
10/27/2005US20050239708 Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
10/27/2005US20050239696 Gmg-3 gmg-4 and gmg-6 polynucleotides and polypeptides and uses thereof
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239069 which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells; gene therapy
10/27/2005US20050238719 Film coating
10/27/2005US20050238670 Immunology response intensifiers; administering a bacterial lysate, for inducing an immune response to Staphylococcus aureus infections
10/27/2005US20050238623 Method for treating mammals with modified mammalian blood
10/27/2005US20050238579 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/27/2005US20050236328 Chitosan-containing polysaccharide, method for preparing the same and use thereof
10/27/2005CA2776927A1 Phosphorylcholine conjugates and corresponding antibodies
10/27/2005CA2563260A1 Methods of treating autoimmune and inflammatory diseases
10/27/2005CA2562694A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/27/2005CA2562369A1 Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
10/27/2005CA2561718A1 Polycyclic pyridines as potassium ion channel modulators
10/27/2005CA2561565A1 Methods for repression of phospholamban gene and modulating cardiac contractility
10/27/2005CA2560346A1 Polycyclic pyridines as potassium ion channel modulators
10/27/2005CA2560336A1 Benzofuranyl derivatives useful for the treatment of cardiac arrhythmia
10/27/2005CA2505469A1 Drug delivery device comprising a bilayered polymeric coating having a cell cycle inhibitor that acts selectively at the g1 phase of the cell cycle incorporated into the first polymer coating layer
10/27/2005CA2503554A1 Dietary supplement
10/26/2005EP1589115A2 Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1589009A1 Vitamin d3 lactone derivative
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1589005A1 Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588726A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588706A2 Use of AT1 receptor antagonists or AT2 receptor modulator for the treatment of conditions or diseases associated with the increase of AT1 or AT2 receptors.
10/26/2005EP1588173A2 Affinity fishing for ligands and proteins receptors
10/26/2005EP1587819A2 Isolation and purification procedure of vasopeptidase peptide inhibitors
10/26/2005EP1587792A1 Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
10/26/2005EP1587779A1 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
10/26/2005EP1587521A1 Bioavailability enhancing activity of carum carvi extracts and fractions thereof
10/26/2005EP1587516A1 Amide and ester matrix metalloproteinase inhibitors
10/26/2005EP1587511A2 Treatment of diseases with alpha-7 nach receptor full agonists
10/26/2005EP1587510A1 Method for treating ischemic stroke with melatonin
10/26/2005EP1587508A1 Therapeutic use of acylglycerols and the nitrogen- and sulphur-containing analogues thereof
10/26/2005EP1587479A2 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
10/26/2005EP1440071B1 Imidazopyridine compounds as 5-ht 4? receptor modulators
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP1397354B1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
10/26/2005EP1381607B1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/26/2005EP1289965B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/26/2005EP1212081B1 Use of ace inhibitors in the prevention of congestive heart failure
10/26/2005EP1185277B1 Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer
10/26/2005EP1107762B1 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure sexual dysfunction in women
10/26/2005EP1003506B1 Use of eprosartan in the treatment of isolated systolic hypertension
10/26/2005EP0625048B2 Synthesis of human procollagens and collagens in recombinant dna systems
10/26/2005CN1688714A Diagnosis and treatment of the tuberous sclerosis pathway
10/26/2005CN1688603A Treatment and prophylaxis with 4-1BB-binding agents
10/26/2005CN1688580A Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688553A Chemical process
10/26/2005CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688540A Novel vinyl carboxylic acid derivatives and their therapeutical use
10/26/2005CN1688534A Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising the
10/26/2005CN1688532A Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
10/26/2005CN1688365A Therapeutic use
10/26/2005CN1688341A Medicinal composition for lowering blood lipid level
10/26/2005CN1688303A Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
10/26/2005CN1688302A Use of hydroxyoleic acid and similar compounds in the production of medicaments
10/26/2005CN1688197A Gene therapy for critical limb ischemia with wild type or mutant eNOS
10/26/2005CN1688196A Hematopoietic stem cells and methods of treatment neogenesis vascular ophthalmopathy
10/26/2005CN1224626C Beta-D-5-thioxylose derivatives, preparation method and therapeutic use
10/26/2005CN1224624C 1, 8-naphthyridin-2 (1H)-one derivatives
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224479C Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224421C Novel specific mechanism for inhibiting adherence of platelets to collagen
10/26/2005CN1224420C Agent for treating visual cell function disorder
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224404C Onion extract with controlling action for angiocardiopathy
10/26/2005CN1224396C Pharmaceutical for treating cardiovascular and cerebrovascular disease
10/25/2005US6958357 Central nervous system disorders; antiallergens; respiratory system disorders
10/25/2005US6958350 Chemical compounds
10/25/2005US6958346 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
1 ... 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 ... 1595